MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530382 | Name: RIPA-56
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RIPA-56 is a potent RIP1 inhibitor. RIPA-56 has RIP1 kinase IC50=13 nM; HT-29 Cell EC50 = 28 nM; in vivo PG: t1/2 = 3.1h. RIPA-56 efficiently reduced tumor necrosis factor alpha (TNFα)-induced mortality and multiorgan damage. Compared to known RIP1 inhibitors, RIPA-56 is potent in both human and murine cells, is much more stable in vivo, and is efficacious in animal model studies.

Chemical Structure

RIPA-56
RIPA-56
CAS#1956370-21-0

Theoretical Analysis

MedKoo Cat#: 530382

Name: RIPA-56

CAS#: 1956370-21-0

Chemical Formula: C13H19NO2

Exact Mass: 221.1416

Molecular Weight: 221.30

Elemental Analysis: C, 70.56; H, 8.65; N, 6.33; O, 14.46

Price and Availability

Size Price Availability Quantity
50mg USD 350.00 2 Weeks
100mg USD 650.00 2 Weeks
200mg USD 1,150.00 2 Weeks
500mg USD 2,300.00 2 Weeks
1g USD 3,250.00 2 Weeks
2g USD 5,250.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RIPA-56; RIPA56; RIPA 56;
IUPAC/Chemical Name
N-benzyl-N-hydroxy-2,2-dimethylbutanamide
InChi Key
AVYVHIKSFXVDBG-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H19NO2/c1-4-13(2,3)12(15)14(16)10-11-8-6-5-7-9-11/h5-9,16H,4,10H2,1-3H3
SMILES Code
CCC(C)(C)C(N(O)CC1=CC=CC=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO and ethanol
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO and ethanol
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
RIPA-56 inhibits receptor interacting serine/threonine kinase 1 (RIPK1; IC50 = 13 nM). RIPA-56 inhibits Z-VAD-FMK-induced necrosis in HT-29 cells (EC50 = 28 nM). In vivo, RIPA-56 (6 mg/kg) reduces TNF-α-induced lethality and protects against TNF-α-induced organ damage and reduces spinal cord demyelination and breakdown of the blood-brain barrier.
In vitro activity:
To be determined
In vivo activity:
The effects of RIPA-56 were observed on day 36 in the mouse model of busulfan-induced gonadotoxicity. RIPA-56 inhibitied necroptosis that caused cell death in busulfan-treated spermatogonial stem cells. The quantities of spermatogonial stem cells and epididymal spermatozoa were restored after RIPA-56 intervention. Reference: Stem Cells Dev. 2020 Apr 15;29(8):475-487. https://pubmed.ncbi.nlm.nih.gov/32024413/
Solvent mg/mL mM
Solubility
Ethanol 44.0 198.83
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 221.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Xie Y, Chen H, Luo D, Yang X, Yao J, Zhang C, Lv L, Guo Z, Deng C, Li Y, Liang X, Deng C, Sun X, Liu G. Inhibiting Necroptosis of Spermatogonial Stem Cell as a Novel Strategy for Male Fertility Preservation. Stem Cells Dev. 2020 Apr 15;29(8):475-487. doi: 10.1089/scd.2019.0220. Epub 2020 Mar 9. PMID: 32024413. 2. Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, Mestiri T, Lagouge M, Foufelle F, Ballenghien F, Ledent T, Moldes M, Cadoret A, Fouassier L, Delaunay JL, Aït-Slimane T, Courtois G, Fève B, Scatton O, Prip-Buus C, Rodrigues CMP, Housset C, Gautheron J. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020 Apr;72(4):627-635. doi: 10.1016/j.jhep.2019.11.008. Epub 2019 Nov 21. PMID: 31760070.
In vitro protocol:
To be determined
In vivo protocol:
1. Xie Y, Chen H, Luo D, Yang X, Yao J, Zhang C, Lv L, Guo Z, Deng C, Li Y, Liang X, Deng C, Sun X, Liu G. Inhibiting Necroptosis of Spermatogonial Stem Cell as a Novel Strategy for Male Fertility Preservation. Stem Cells Dev. 2020 Apr 15;29(8):475-487. doi: 10.1089/scd.2019.0220. Epub 2020 Mar 9. PMID: 32024413. 2. Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, Mestiri T, Lagouge M, Foufelle F, Ballenghien F, Ledent T, Moldes M, Cadoret A, Fouassier L, Delaunay JL, Aït-Slimane T, Courtois G, Fève B, Scatton O, Prip-Buus C, Rodrigues CMP, Housset C, Gautheron J. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020 Apr;72(4):627-635. doi: 10.1016/j.jhep.2019.11.008. Epub 2019 Nov 21. PMID: 31760070.
1: Feng L, Dai S, Zhang C, Zhang W, Zhu W, Wang C, He Y, Song W. Ripa-56 protects retinal ganglion cells in glutamate-induced retinal excitotoxic model of glaucoma. Sci Rep. 2024 Feb 15;14(1):3834. doi: 10.1038/s41598-024-54075-z. PMID: 38360971; PMCID: PMC10869350. 2: Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, Mestiri T, Lagouge M, Foufelle F, Ballenghien F, Ledent T, Moldes M, Cadoret A, Fouassier L, Delaunay JL, Aït-Slimane T, Courtois G, Fève B, Scatton O, Prip-Buus C, Rodrigues CMP, Housset C, Gautheron J. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020 Apr;72(4):627-635. doi: 10.1016/j.jhep.2019.11.008. Epub 2019 Nov 21. PMID: 31760070. 3: Yu Q, Chen Y, Zhao Y, Huang S, Xin X, Jiang L, Wang H, Wu W, Qu L, Xiang C, Wang S, Liu G, Yang L. Nephropathy Is Aggravated by Fatty Acids in Diabetic Kidney Disease through Tubular Epithelial Cell Necroptosis and Is Alleviated by an RIPK-1 Inhibitor. Kidney Dis (Basel). 2023 Mar 17;9(5):408-423. doi: 10.1159/000529995. PMID: 37927402; PMCID: PMC10624943. 4: Xie Y, Chen H, Luo D, Yang X, Yao J, Zhang C, Lv L, Guo Z, Deng C, Li Y, Liang X, Deng C, Sun X, Liu G. Inhibiting Necroptosis of Spermatogonial Stem Cell as a Novel Strategy for Male Fertility Preservation. Stem Cells Dev. 2020 Apr 15;29(8):475-487. doi: 10.1089/scd.2019.0220. Epub 2020 Mar 9. PMID: 32024413. 5: Mago E, Zhao X, Zhang W, Shao Q, Li P, Huang S, Ding X, Liu H, Sun T, He F, Weng D. RIP1 kinase inactivation protects against LPS-induced acute respiratory distress syndrome in mice. Int Immunopharmacol. 2024 May 30;133:112060. doi: 10.1016/j.intimp.2024.112060. Epub 2024 Apr 23. PMID: 38652970. 6: Ren Y, Su Y, Sun L, He S, Meng L, Liao D, Liu X, Ma Y, Liu C, Li S, Ruan H, Lei X, Wang X, Zhang Z. Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome. J Med Chem. 2017 Feb 9;60(3):972-986. doi: 10.1021/acs.jmedchem.6b01196. Epub 2017 Jan 5. PMID: 27992216. 7: Zhang S, Su Y, Ying Z, Guo D, Pan C, Guo J, Zou Z, Wang L, Zhang Z, Jiang Z, Zhang Z, Wang X. RIP1 kinase inhibitor halts the progression of an immune- induced demyelination disease at the stage of monocyte elevation. Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5675-5680. doi: 10.1073/pnas.1819917116. Epub 2019 Mar 5. PMID: 30837313; PMCID: PMC6431233.